Forbion, a prominent European life sciences venture firm, has successfully raised 2 billion euros (over $2.2 billion) for its latest investment initiatives.
The firm announced that its Forbion Growth Opportunities III fund attracted 1.2 billion euros, while the Forbion Ventures VII fund secured 890 million euros. Both funds surpassed their initial fundraising targets, contributing to a total asset management portfolio exceeding 5 billion euros.
The Forbion Growth Opportunities III fund is strategically focused on later-stage biotechnology companies across North America and Europe, while the Forbion Ventures VII fund primarily targets earlier-stage therapeutics startups, including new ventures that the firm actively develops. Each fund is expected to invest in approximately 15 companies.
Forbion has maintained a steady investment pace, currently holding 58 active investments and having made a total of 128 investments since its inception over two decades ago.
Forbion's recent fundraising is bolstered by a series of successful exits, particularly in the pharmaceutical sector. Notably, Aiolos Bio, a developer of lung drugs, was acquired by GSK for $1 billion in January. Additionally, other portfolio companies, including Mariana Oncology and Yellow Jersey Therapeutics, have also been acquired in deals exceeding $1 billion this year.
Forbion's strategic focus on both later-stage and early-stage investments positions it uniquely within the biotechnology landscape. By balancing its portfolio with a mix of established companies and emerging startups, the firm aims to foster innovation and drive advancements in healthcare.
The commitment to supporting a diverse range of biotech firms is crucial, especially as the industry faces ongoing challenges related to funding and market dynamics. As Forbion continues to navigate the complexities of the biotechnology investment landscape, its recent fundraising achievements and successful exits serve as a testament to its strategic vision and operational expertise.
The firm’s proactive approach to investment, coupled with its ability to adapt to changing market conditions, positions it as a leader in the European life sciences venture capital space. With a robust pipeline of investments and a commitment to supporting the growth of innovative companies, Forbion is poised to play a significant role in shaping the future of biotechnology.